Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine

Status Completed

Clinical Trial Summary

We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders

Clinical Trial Description

Major depressive episodes (MDE) frequently occur during the course of schizophrenic psychoses, both as as "post-psychotic" depressions, and also independently from psychotic episodes. A number of clinical studies reported the application of different antidepressive substances, such as Imipramine, Reboxetine or Venlafaxine. In general, the treatment of schizophrenic patients with antidepressive drugs can be considered as necessary and save, resulting in therapeutic guidelines of different psychiatric societies. However, since 5 to 10 % of the schizophrenic patients commit suicide, there is still much effort necessary in order to improve the treatment of affective symptoms in schizophrenic psychoses.The recently introduced antidepressive substance Duloxetine selectively inhibits as a SSNRI the reuptake of serotonine and noradrenaline from the synaptic cleft. Duloxetine was proven as antidepressive, anxiolytic and analgetic in a series of multi-centre, placebo-controlled investigations. Based on these considerations and on successful experiences in single case reports we aim to investigate the therapeutic effects of duloxetine in patients with lifetime diagnoses of the schizophrenic spectrum. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00224302
Study type	Interventional
Source	Central Institute of Mental Health, Mannheim
Contact
Status	Completed
Phase	Phase 4
Start date	August 2005
Completion date	November 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Terminated	`NCT03230097` - This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year	Phase 2
Completed	`NCT03497663` - VIA Family - Family Based Early Intervention Versus Treatment as Usual	N/A
Active, not recruiting	`NCT05726617` - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders	N/A
Not yet recruiting	`NCT03807388` - ReMindCare App for Patients From First Episode of Psychosis Unit.	N/A
Recruiting	`NCT02874573` - Tocilizumab in Schizophrenia	Phase 1
Completed	`NCT02906553` - The Role of Nitric Oxide in Cognition in Schizophrenia	N/A
Terminated	`NCT02584114` - Brain Effects of Memory Training in Early Psychosis	N/A
Completed	`NCT01981356` - Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis	Phase 0
Withdrawn	`NCT02213887` - Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications	Phase 4
Terminated	`NCT02841956` - Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement	N/A
Recruiting	`NCT02009969` - Serial Comparisons of Abdominal and Neurological MRI Scans	N/A
Recruiting	`NCT02848469` - Irish Omega-3 Study	Phase 2
Completed	`NCT02648321` - Motivational Intervention for Physical Activity in Psychosis	N/A
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00484302` - Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis	N/A
Completed	`NCT00455234` - Rapid Tranquillization Trial: TREC-India II	Phase 3
Completed	`NCT00844922` - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)	Phase 2
Completed	`NCT00130923` - Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder	Phase 4
Completed	`NCT00253240` - Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population